GO:0042531 positive regulation of tyrosine phosphorylation of STAT protein: Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0042531 describes any process that increases the phosphorylation of tyrosine residues on STAT (Signal Transducer and Activator of Transcription) proteins.
• JAK kinases are the principal enzymes that phosphorylate STAT proteins on tyrosine residues, and their activity is targeted by approved inhibitors.
• Protein tyrosine phosphatases such as SHP2 (PTPN11) and PTPN6 can both promote and restrain STAT tyrosine phosphorylation depending on context [1,4,5].
• Aberrant positive regulation of STAT tyrosine phosphorylation drives hematological malignancies and solid tumors, making it a major therapeutic target [1,2,6].
• STAT1 tyrosine phosphorylation is enhanced in autoimmune and inflammatory conditions, including HLA-B27-associated disease [7,8].
• CRISPR knockout, point-mutation, knock-in, and overexpression models are essential to dissect causal roles of regulators of STAT tyrosine phosphorylation [1,3].
Description
GO:0042531, positive regulation of tyrosine phosphorylation of STAT protein, is a biological process term that captures any mechanism that increases the addition of phosphate groups to tyrosine residues on STAT proteins. STAT proteins are latent cytoplasmic transcription factors that become activated when Janus kinases (JAKs) or other tyrosine kinases phosphorylate a conserved tyrosine near the C-terminus. This modification triggers STAT dimerization, nuclear translocation, and transcriptional activation of target genes involved in immunity, proliferation, and survival. Because this process is central to cytokine and growth factor signaling, its dysregulation is implicated in cancer, autoimmunity, and inflammatory disorders [2,6]. Researchers study GO:0042531 to understand how extracellular cues are converted into transcriptional programs and to identify drug targets that modulate JAK-STAT signaling. The term encompasses positive regulation by kinases, adaptor proteins, and phosphatases that indirectly enhance STAT tyrosine phosphorylation [1,4,5].
positive regulation of tyrosine phosphorylation of STAT protein At A Glance
| GO ID | GO:0042531 |
|---|---|
| GO term | positive regulation of tyrosine phosphorylation of STAT protein |
| Ontology | biological_process |
| Synonym | activation of tyrosine phosphorylation of STAT protein; upregulation of tyrosine phosphorylation of STAT protein; stimulation of tyrosine phosphorylation of STAT protein |
| Major function | Increases tyrosine phosphorylation of STAT proteins, promoting STAT dimerization, nuclear translocation, and transcription of target genes [1,3] |
| Key enzymes | JAK family kinases (JAK1, JAK2, JAK3, TYK2) and SRC family kinases |
| Key phosphatases | SHP2 (PTPN11), PTPN6 (SHP1), and other tyrosine phosphatases that modulate phospho-STAT levels [1,4,5] |
| Associated diseases | Leukemia, lymphoma, solid tumors, autoimmune diseases, and inflammatory disorders [1,2,6,7,8] |
What Is GO:0042531?
In simple terms, GO:0042531 refers to any cellular process that activates or increases the frequency, rate, or extent of adding a phosphate group to a tyrosine residue of a STAT protein. This includes direct kinase activity, recruitment of kinases to STAT proteins, inhibition of phosphatases that remove the phosphate, and any signaling event that ultimately elevates phospho-tyrosine STAT levels [1,3].
Why Is positive regulation of tyrosine phosphorylation of STAT protein Important in Cell Biology?
Positive regulation of STAT tyrosine phosphorylation is a central node in cytokine and growth factor signaling, controlling immune responses, cell proliferation, differentiation, and survival [1,3]. Its dysregulation is a hallmark of many cancers, where constitutive STAT3 or STAT5 tyrosine phosphorylation drives oncogenesis [1,6]. In autoimmune diseases, enhanced STAT1 tyrosine phosphorylation contributes to chronic inflammation [7,8]. Understanding this process is therefore critical for developing targeted therapies, including JAK inhibitors and phosphatase modulators [2,3].
• Drives oncogenic signaling in leukemia, lymphoma, and solid tumors through constitutive STAT3/STAT5 activation [1,6].
• Mediates immune and inflammatory responses via cytokine receptor signaling.
• Is a validated drug target for JAK inhibitors such as ruxolitinib and tofacitinib.
• Modulated by tyrosine phosphatases SHP2 and PTPN6, which can act as oncogenes or tumor suppressors [1,2,5].
• Contributes to autoimmune pathology, including HLA-B27-associated diseases [7,8].
• Essential for normal development and hematopoiesis.
• Involved in resistance to targeted therapies, such as imatinib in BCR-ABL-positive leukemia.
• Provides biomarkers for patient stratification in cancer and inflammatory diseases.
• Enables high-throughput CRISPR screening to identify novel regulators.
• Supports development of combination therapies targeting JAK-STAT and parallel pathways [2,3].
What Happens During positive regulation of tyrosine phosphorylation of STAT protein?
Cytokine or growth factor binding to receptors
In simple terms: A signal molecule docks onto a receptor on the cell surface, waking up the cell.
Extracellular ligands such as interferons, interleukins, and growth factors bind to their cognate receptors, inducing receptor dimerization or conformational changes that bring associated JAK kinases into proximity. This event is the initial step that ultimately leads to STAT tyrosine phosphorylation.
JAK kinase activation and receptor phosphorylation
In simple terms: The receptor-associated kinases add phosphate tags to each other and to the receptor.
Upon ligand binding, JAK kinases (JAK1, JAK2, JAK3, TYK2) trans-phosphorylate each other and phosphorylate tyrosine residues on the receptor cytoplasmic domain. These phosphotyrosines serve as docking sites for STAT proteins via their SH2 domains.
STAT recruitment and tyrosine phosphorylation
In simple terms: STAT proteins are grabbed by the receptor and get tagged with phosphate.
STAT proteins bind to the phosphorylated receptor through their SH2 domains and are subsequently phosphorylated on a conserved tyrosine residue (e.g., Y705 in STAT3, Y701 in STAT1) by JAKs or other kinases [1,3]. This phosphorylation is the defining event of GO:0042531.
STAT dimerization and nuclear translocation
In simple terms: Tagged STATs pair up and move into the nucleus to turn on genes.
Phosphorylated STATs form dimers via reciprocal SH2-phosphotyrosine interactions, translocate to the nucleus, and bind DNA to regulate transcription of target genes involved in proliferation, survival, and immune responses [1,3].
Modulation by phosphatases and negative feedback
In simple terms: Phosphatases can erase the phosphate tags, tuning the signal.
Protein tyrosine phosphatases such as SHP2 (PTPN11) and PTPN6 (SHP1) can dephosphorylate STAT proteins or upstream kinases, thereby attenuating or shaping the positive regulation of STAT tyrosine phosphorylation [1,4,5]. In some contexts, SHP2 positively regulates STAT signaling by modulating receptor phosphorylation.
Key Genes Involved in GO:0042531 positive regulation of tyrosine phosphorylation of STAT protein
The following genes and proteins are central to the positive regulation of tyrosine phosphorylation of STAT proteins, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| JAK1 | Tyrosine kinase that phosphorylates STAT1, STAT2, STAT3, STAT5 | Target of JAK inhibitors; mutated in cancers and immune disorders |
| JAK2 | Phosphorylates STAT3 and STAT5; key in myeloproliferative neoplasms | V617F mutation drives constitutive STAT phosphorylation [1,3] |
| JAK3 | Phosphorylates STAT5 in lymphoid cells | Target in autoimmune diseases and leukemia |
| TYK2 | Phosphorylates STAT1 and STAT2 in interferon signaling | Associated with autoimmune diseases |
| STAT1 | Transcription factor; tyrosine phosphorylation at Y701 | Central to interferon responses and inflammation [7,8] |
| STAT3 | Transcription factor; tyrosine phosphorylation at Y705 | Oncogenic driver in many cancers [1,6] |
| STAT5A | Transcription factor; phosphorylated by JAK2 | Key in hematopoiesis and leukemia |
| STAT5B | Transcription factor; phosphorylated by JAK2 | Implicated in growth and immune regulation |
| PTPN11 (SHP2) | Tyrosine phosphatase that can positively regulate STAT phosphorylation | Oncogene in leukemia and solid tumors [1,4] |
| PTPN6 (SHP1) | Tyrosine phosphatase that modulates JAK/STAT signaling | Tumor suppressor and immune regulator |
| BCR-ABL | Fusion kinase that activates STAT5 tyrosine phosphorylation | Target of imatinib in CML |
| IRF | Interferon regulatory factor that positively regulates JAK/STAT pathway | Innate immunity in shrimp and mammals |
| PKR | Double-stranded RNA-dependent protein kinase that enhances STAT1 phosphorylation | Inflammation and HLA-B27-associated disease |
| Aiolos (IKZF3) | Transcription factor that promotes IFN-γ/STAT1 signaling | Th1 cell differentiation and autoimmunity |
| IL6ST (gp130) | Cytokine receptor subunit that activates JAK-STAT3 | Inflammation and cancer |
| IFNAR1 | Interferon-alpha receptor subunit that activates JAK-STAT1/2 | Antiviral and autoimmune responses |
| CSF2RB | GM-CSF receptor subunit that activates JAK2-STAT5 | Myeloid cell proliferation |
| EPOR | Erythropoietin receptor that activates JAK2-STAT5 | Erythropoiesis and leukemia |
How Is positive regulation of tyrosine phosphorylation of STAT protein Regulated?
Positive regulation of STAT tyrosine phosphorylation is tightly controlled by multiple mechanisms. JAK kinases are negatively regulated by SOCS proteins and phosphatases such as SHP1 and SHP2 [1,4,5]. SHP2 can also positively regulate STAT phosphorylation by dephosphorylating inhibitory sites on JAKs or receptors. In BCR-ABL-positive cells, imatinib and Ara-C modulate STAT5 tyrosine phosphorylation, integrating signals from different pathways. Interferon regulatory factors can positively regulate the JAK/STAT pathway in innate immunity. Additionally, PKR enhances STAT1 phosphorylation in response to double-stranded RNA. These layers of regulation ensure appropriate signal strength and duration.
positive regulation of tyrosine phosphorylation of STAT protein and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| JAK2 | Myeloproliferative neoplasms, leukemia | Knock-in of JAK2 V617F in cell lines; KO to assess drug response [1,3] |
| STAT3 | Solid tumors, leukemia, autoimmunity | Point mutation at Y705 to prevent phosphorylation; KO for proliferation assays [1,6] |
| PTPN11 (SHP2) | Juvenile myelomonocytic leukemia, solid tumors | Knockout and point mutation (e.g., E76K) to study STAT activation [1,4] |
| STAT1 | Autoinflammatory diseases, HLA-B27-associated arthritis | Knockout and phospho-mimetic knock-in to study interferon responses [7,8] |
| BCR-ABL | Chronic myeloid leukemia | Knock-in of BCR-ABL fusion; KO to test imatinib sensitivity |
Cancer
Constitutive activation of STAT3 and STAT5 tyrosine phosphorylation is a hallmark of many cancers, including leukemias, lymphomas, and solid tumors [1,6]. Oncogenic mutations in JAK2 (V617F) or BCR-ABL fusion drive persistent STAT phosphorylation, promoting proliferation and survival [1,6]. SHP2 (PTPN11) mutations are found in juvenile myelomonocytic leukemia and other malignancies, where they aberrantly enhance STAT signaling. Targeting positive regulators of STAT tyrosine phosphorylation is a major therapeutic strategy [2,3].
Autoimmune and inflammatory diseases
Enhanced STAT1 tyrosine phosphorylation contributes to chronic inflammation in autoimmune diseases such as rheumatoid arthritis and HLA-B27-associated disorders [7,8]. Aiolos promotes IFN-γ/STAT1 signaling in Th1 cells, linking transcription factor networks to STAT activation. PKR-dependent STAT1 phosphorylation is observed in HLA-B27-expressing cells, suggesting a role in spondyloarthritis. JAK inhibitors are approved for rheumatoid arthritis and other inflammatory conditions.
Infectious and immune disorders
Proper regulation of STAT tyrosine phosphorylation is essential for antiviral and antibacterial immunity [3,5]. In shrimp, PTPN6 mediates a positive regulatory link from interferon regulatory factors to the JAK/STAT pathway, highlighting evolutionary conservation. Dysregulated STAT signaling can lead to immunodeficiency or excessive inflammation.
From positive regulation of tyrosine phosphorylation of STAT protein-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate gene reduce STAT tyrosine phosphorylation? | CRISPR knockout cell line followed by phospho-STAT Western blot |
| Does a specific tyrosine residue on STAT drive oncogenic transcription? | Point mutation (Y-to-F) knock-in via CRISPR [1,6] |
| Does a disease-associated mutation in JAK2 enhance STAT phosphorylation? | Knock-in of mutant allele (e.g., JAK2 V617F) [1,3] |
| Where does phospho-STAT localize in live cells? | Tagged knock-in of STAT with fluorescent protein |
| Does overexpression of a phosphatase reduce STAT phosphorylation? | Overexpression cell model with doxycycline-inducible vector [4,5] |
| Which genes regulate STAT tyrosine phosphorylation genome-wide? | CRISPR library screening with phospho-STAT readout |
How to Study the positive regulation of tyrosine phosphorylation of STAT protein Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Phospho-STAT Western blot | Levels of tyrosine-phosphorylated STAT proteins | Validation of pathway activation or inhibition [1,6] |
| Immunoprecipitation | Protein-protein interactions and specific phospho-isoforms | Confirm STAT dimerization or phosphatase association |
| CRISPR knockout screen | Genes required for STAT tyrosine phosphorylation | Discovery of novel regulators |
| RNA-seq | Transcriptional changes downstream of STAT activation | Identify target genes and pathways |
| Phosphoproteomics | Global tyrosine phosphorylation events | Unbiased profiling of signaling networks |
| Luciferase reporter assay | STAT transcriptional activity | High-throughput drug screening |
| Flow cytometry | Phospho-STAT levels in single cells | Analyze heterogeneity in cell populations |
| Proximity ligation assay | In situ detection of phospho-STAT interactions | Visualize signaling complexes in fixed cells |
Phospho-specific Western blotting and immunoprecipitation
Western blotting with antibodies against phospho-STAT (e.g., pY701-STAT1, pY705-STAT3) is the standard method to measure changes in STAT tyrosine phosphorylation [1,6]. Immunoprecipitation followed by immunoblotting can confirm specific modifications and interactions.
CRISPR screening and functional genomics
Genome-wide CRISPR knockout or activation screens coupled with phospho-STAT staining or reporter assays can identify novel positive regulators of STAT tyrosine phosphorylation. These screens are powerful for discovering drug targets and understanding signaling networks.
Transcriptional reporter assays and RNA-seq
STAT-responsive luciferase reporters and RNA sequencing measure downstream transcriptional output of STAT activation [1,3]. These methods link tyrosine phosphorylation to gene expression changes and can validate functional consequences.
Proteomics and phosphoproteomics
Mass spectrometry-based phosphoproteomics enables unbiased quantification of STAT tyrosine phosphorylation and identification of co-regulated signaling events. This approach can reveal crosstalk with other pathways and potential feedback mechanisms.
How CRISPR Can Be Used to Study GO:0042531 positive regulation of tyrosine phosphorylation of STAT protein
Knockout
CRISPR knockout of JAK kinases, STAT proteins, or phosphatases such as PTPN11 and PTPN6 can abolish or enhance STAT tyrosine phosphorylation, providing causal evidence for their roles [1,4,5]. Knockout cell lines are essential for validating drug targets and understanding pathway architecture.
Point Mutation
Introducing point mutations such as STAT3 Y705F or JAK2 V617F via CRISPR allows precise interrogation of phosphorylation sites and disease-associated variants [1,6]. These models help distinguish between phosphorylation-dependent and independent functions.
Knock-in
Knock-in of tagged STAT proteins (e.g., GFP-STAT1) or disease alleles enables live-cell imaging and physiological expression studies. Knock-in models are valuable for tracking STAT localization and dynamics.
Overexpression
Overexpression of wild-type or mutant JAKs, STATs, or phosphatases can amplify or suppress STAT tyrosine phosphorylation, facilitating biochemical and drug sensitivity studies [4,5]. Inducible overexpression systems allow temporal control of pathway activation.
How EDITGENE Supports positive regulation of tyrosine phosphorylation of STAT protein Research
Researchers studying positive regulation of tyrosine phosphorylation of STAT protein-related genes often need to determine whether a candidate gene is causally involved in STAT activation, whether a specific phosphorylation site is required for downstream effects, or whether a disease-associated mutation alters signaling output. EDITGENE provides custom CRISPR cell models and screening services to answer these questions with rigor and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of tyrosine phosphorylation of STAT protein research.
Frequently Asked Questions About positive regulation of tyrosine phosphorylation of STAT protein
What is GO:0042531?
GO:0042531 is a Gene Ontology biological process term defined as any process that activates or increases the frequency, rate, or extent of adding a phosphate group to a tyrosine residue of a STAT protein.
What genes are involved in positive regulation of tyrosine phosphorylation of STAT protein?
Key genes include JAK1, JAK2, JAK3, TYK2, STAT1, STAT3, STAT5A, STAT5B, PTPN11 (SHP2), PTPN6 (SHP1), and BCR-ABL, among others [1,3,4,5,6].
Which kinases phosphorylate STAT proteins on tyrosine?
JAK family kinases (JAK1, JAK2, JAK3, TYK2) are the primary tyrosine kinases that phosphorylate STAT proteins, although SRC family kinases can also contribute.
How is STAT tyrosine phosphorylation regulated?
It is positively regulated by cytokine receptor activation and JAK kinase activity, and negatively regulated by phosphatases such as SHP1 and SOCS proteins [1,4,5].
What diseases are associated with abnormal STAT tyrosine phosphorylation?
Cancers such as leukemia and solid tumors, as well as autoimmune and inflammatory diseases, are associated with dysregulated STAT tyrosine phosphorylation [1,2,6,7,8].
What is the role of SHP2 in STAT phosphorylation?
SHP2 (PTPN11) can both positively and negatively regulate STAT tyrosine phosphorylation depending on context, and its mutations are oncogenic [1,4].
How can I study positive regulation of STAT tyrosine phosphorylation?
Common methods include phospho-STAT Western blotting, immunoprecipitation, CRISPR screens, RNA-seq, and phosphoproteomics [1,3,6].
What are the best CRISPR models for studying STAT phosphorylation?
Knockout of kinases or phosphatases, point mutation of STAT tyrosine residues, and knock-in of disease alleles are widely used [1,6].
Is STAT1 tyrosine phosphorylation important in autoimmunity?
Yes, enhanced STAT1 tyrosine phosphorylation is observed in autoimmune conditions such as HLA-B27-associated diseases and is linked to IFN-γ signaling [7,8].
What is the clinical relevance of JAK inhibitors?
JAK inhibitors block tyrosine phosphorylation of STAT proteins and are approved for myeloproliferative neoplasms, rheumatoid arthritis, and other inflammatory diseases.
Conclusion
GO:0042531, positive regulation of tyrosine phosphorylation of STAT protein, is a fundamental biological process that integrates cytokine and growth factor signals into transcriptional programs. Its dysregulation underlies cancer, autoimmunity, and inflammatory diseases, making it a prime target for therapeutic intervention [1,2,3]. CRISPR-based models and functional genomics are indispensable for dissecting the causal roles of individual regulators and for accelerating drug discovery [1,6]. EDITGENE provides comprehensive services to support these research efforts.
References
- 1. Asmamaw MD et al.. 2022. A comprehensive review of SHP2 and its role in cancer.. Cell Oncol (Dordr) 45(5):729-753 PMID: 36066752
- 2. Frankson R et al.. 2017. Therapeutic Targeting of Oncogenic Tyrosine Phosphatases.. Cancer Res 77(21):5701-5705 PMID: 28855209
- 3. Thompson JE. 2005. JAK protein kinase inhibitors.. Drug News Perspect 18(5):305-10 PMID: 16193102
- 4. Servidei T et al.. 1998. Coordinate regulation of STAT signaling and c-fos expression by the tyrosine phosphatase SHP-2.. J Biol Chem 273(11):6233-41 PMID: 9497348
- 5. Luo M et al.. 2022. The Non-Receptor Protein Tyrosine Phosphatase PTPN6 Mediates a Positive Regulatory Approach From the Interferon Regulatory Factor to the JAK/STAT Pathway in Litopenaeus vannamei.. Front Immunol 13:913955 PMID: 35844582
- 6. Kindler T et al.. 2003. In BCR-ABL-positive cells, STAT-5 tyrosine-phosphorylation integrates signals induced by imatinib mesylate and Ara-C.. Leukemia 17(6):999-1009 PMID: 12764361
- 7. Leonard MR et al.. 2024. Aiolos promotes CXCR3 expression on Th1 cells via positive regulation of IFN-γ/STAT1 signaling.. JCI Insight 10(1) PMID: 39560988
- 8. Ruuska M et al.. 2012. Enhanced phosphorylation of STAT-1 is dependent on double-stranded RNA-dependent protein kinase signaling in HLA-B27-expressing U937 monocytic cells.. Arthritis Rheum 64(3):772-7 PMID: 21968657
